Key result
Sacubitril/valsartan significantly reversed pathological injuries in the heart and vascular endothelium and decreased fibrotic factors in rats with high-salt diet-induced HFpEF.
Why the study?
Although clinical efficacy of sacubitril/valsartan is confirmed for HFrEF, its role in heart failure with preserved ejection fraction remains unclear.
Does sacubitril/valsartan alleviate high-salt diet-induced HFpEF and fibrosis in rats?
Does sacubitril/valsartan alleviate high-salt diet-induced HFpEF and fibrosis in rats?
Sacubitril/valsartan alleviates high-salt diet-induced HFpEF in rats by inhibiting fibrosis via the TGF-β1/Smad3 signaling pathway.
Does not inform clinical HFpEF care; leaves open translation of antifibrotic effects from rat models.
Previous studies have confirmed the clinical efficacy of sacubitril/valsartan (Sac/Val) for the treatment of heart failure with reduced ejection fraction (HFrEF). However, the role of Sac/Val in heart failure with preserved ejection fraction (HFpEF) remains unclear. Sac/Val is a combination therapeutic medicine comprising sacubitril and valsartan that acts as a first angiotensin receptor blocker and neprilysin inhibitor (angiotensin-receptor neprilysin inhibitor (ARNI)). Here, we investigated the role of Sac/Val in high-salt diet-induced HFpEF coupled with vascular injury as well as the underlying mechanism. Rats were fed with high-salt feed, followed by intragastric administration of Sac/Val (68 mg/kg; i.g.). The results of functional tests revealed that a high-salt diet caused pathological injuries in the heart and vascular endothelium, which were significantly reversed by treatment with Sac/Val. Moreover, Sac/Val significantly decreased the levels of fibrotic factors, including type I collagen and type Ⅲ collagen, thus, reducing the ratio of MMP2/TIMP2 while increasing Smad7 levels. Further investigation suggested that Sac/Val probably reversed the effects of high-salt diet-induced HFpEF by inhibiting the activation of the TGF-β1/Smad3 signaling pathway. Thus, treatment with Sac/Val effectively alleviated the symptoms of high-salt diet-induced HFpEF, probably by inhibiting fibrosis via the TGF-β1/Smad3 signaling pathway, supporting the therapeutic potential of Sac/Val for the treatment of HFpEF.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2021) studied Heart failure with preserved ejection fraction (HFpEF). Sacubitril/Valsartan was evaluated on Pathological injuries in the heart and vascular endothelium and levels of fibrotic factors. Sacubitril/valsartan significantly reversed pathological injuries in the heart and vascular endothelium and decreased fibrotic factors in rats with high-salt diet-induced HFpEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: